Arkolith/Insider Trading/BCAX/Form 4

Mazumdar Claire

Chief Executive Officer, DirectorBicara Therapeutics Inc. (BCAX) · full profile →Form 4 · filed Mar 11, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$705K
Net Open-Market Flow
-$705K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 9, 2026Sell(S)37K$19.17$705K339K
Mar 9, 2026Option exercise(M)37K$3.79$139K376K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 9, 2026Option exercise(M)37K—$0191K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001628280-26-016874) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML